Literature DB >> 15958079

Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis.

K Mitsuyama1, A Suzuki, S Matsumoto, N Tomiyasu, K Takaki, H Takedatsu, J Masuda, K Handa, K Harada, H Nishida, A Toyonaga, M Sata.   

Abstract

Infiltration by circulating inflammatory cells is a prominent local inflammatory feature of ulcerative colitis (UC). Several trials have suggested that leukocytapheresis by filtration can benefit patients with active UC. We investigated how this therapy might modulate the inflammatory response. Patients with active UC who were beginning repeated filtration leukocytapheresis were studied. Mononuclear cell preparations were obtained from blood before and after the first treatment, and expression of cytokine signalling components and the cell-proliferative response were analysed in vitro. Leukocytapheresis reduced lipopolysaccharide-induced production of proinflammatory cytokines (interleukin-1, -6, -8 and tumour necrosis factor-alpha, P < 0.05 for all) and activation of intracellular signalling components (nuclear factor-kappaB, mitogen-activated protein kinases, and signal transducer and activator of transcription-3), as well as surface expression of toll-like receptor-4 (P < 0.05) in mononuclear cells. The therapy also reduced the cell-proliferative response by mononuclear cells stimulated with sonicated bacterial preparations from autologous intestine (P < 0.05). These results indicate that activated mononuclear cells in the peripheral blood of patients with active UC are removed by leukocytapheresis and replaced by cells with a lower activation status. This replacement may partly explain the therapeutic benefit.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958079      PMCID: PMC1809412          DOI: 10.1111/j.1365-2249.2005.02825.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  64 in total

1.  The role of interferon gamma in the pathogenesis of Crohn's disease.

Authors:  T Sasaki; N Hiwatashi; H Yamazaki; M Noguchi; T Toyota
Journal:  Gastroenterol Jpn       Date:  1992-02

2.  MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways.

Authors:  R Medzhitov; P Preston-Hurlburt; E Kopp; A Stadlen; C Chen; S Ghosh; C A Janeway
Journal:  Mol Cell       Date:  1998-08       Impact factor: 17.970

3.  Treatment of diversion colitis with short-chain-fatty acid irrigation.

Authors:  J M Harig; K H Soergel; R A Komorowski; C M Wood
Journal:  N Engl J Med       Date:  1989-01-05       Impact factor: 91.245

4.  Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine.

Authors:  T T MacDonald; P Hutchings; M Y Choy; S Murch; A Cooke
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

5.  Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.

Authors:  R Duchmann; E Schmitt; P Knolle; K H Meyer zum Büschenfelde; M Neurath
Journal:  Eur J Immunol       Date:  1996-04       Impact factor: 5.532

6.  p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease.

Authors:  Georg H Waetzig; Dirk Seegert; Philip Rosenstiel; Susanna Nikolaus; Stefan Schreiber
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

7.  Colonic mucosal interleukin-6 in inflammatory bowel disease.

Authors:  K Mitsuyama; E Sasaki; A Toyonaga; H Ikeda; O Tsuruta; A Irie; N Arima; T Oriishi; K Harada; K Fujisaki
Journal:  Digestion       Date:  1991       Impact factor: 3.216

8.  Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)

Authors:  R Duchmann; I Kaiser; E Hermann; W Mayet; K Ewe; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

9.  Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease.

Authors:  M F Neurath; I Fuss; G Schürmann; S Pettersson; K Arnold; H Müller-Lobeck; W Strober; C Herfarth; K H Büschenfelde
Journal:  Ann N Y Acad Sci       Date:  1998-11-17       Impact factor: 5.691

10.  Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis.

Authors:  Y R Mahida; M Ceska; F Effenberger; L Kurlak; I Lindley; C J Hawkey
Journal:  Clin Sci (Lond)       Date:  1992-03       Impact factor: 6.124

View more
  5 in total

1.  Critical comment: analyzing the effect of novel therapies on cytokine expression in inflammatory bowel disease: do cytokine levels reflect clinical response?

Authors:  B M Wittig; M Zeitz
Journal:  Int J Colorectal Dis       Date:  2006-01-17       Impact factor: 2.571

2.  Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis.

Authors:  Yuhki Yagi; Akira Andoh; Osamu Inatomi; Shigeki Bamba; Tomoyuki Tsujikawa; Yoshihide Fujiyama; Keiichi Mitsuyama; Takashi Yoshida
Journal:  J Gastroenterol       Date:  2006-06       Impact factor: 7.527

3.  Leukocytapheresis Therapy Improved Cholestasis in a Patient Suffering from Primary Sclerosing Cholangitis with Ulcerative Colitis.

Authors:  Minoru Itou; Keiichi Mitsuyama; Takumi Kawaguchi; Yoshinobu Okabe; Hideya Suga; Junya Masuda; Hiroshi Yamasaki; Kotaro Kuwaki; Eitaro Taniguchi; Masaru Harada; Osamu Tsuruta; Michio Sata
Journal:  Case Rep Gastroenterol       Date:  2009-04-15

4.  Leukocytapheresis for the treatment of active pouchitis: a pilot study.

Authors:  Yasumi Araki; Keiichi Mitsuyama; Takaaki Nagae; Yuji Tou; Motonori Nakagawa; Yasue Iwatani; Masakazu Harada; Hiroyuki Ozasa; Michio Sata; Toshihiro Noake
Journal:  J Gastroenterol       Date:  2008-07-23       Impact factor: 7.527

5.  Mechanisms underlying the effects of leukocyte apheresis with a fiber filter in a rat model of dextran sulfate sodium-induced colitis.

Authors:  Hiroshi Yamasaki; Keiichi Mitsuyama; Junya Masuda; Nobuo Tomiyasu; Hiroko Takedatsu; Hirotada Akashi; Satoshi Matsumoto; Hidetoshi Takedatsu; Kotaro Kuwaki; Osamu Tsuruta; Michio Sata
Journal:  Dig Dis Sci       Date:  2009-03-04       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.